MX2023005841A - Anticuerpos anti-marco y usos de estos. - Google Patents

Anticuerpos anti-marco y usos de estos.

Info

Publication number
MX2023005841A
MX2023005841A MX2023005841A MX2023005841A MX2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A
Authority
MX
Mexico
Prior art keywords
marco
antibodies
marco antibodies
generating
methods
Prior art date
Application number
MX2023005841A
Other languages
English (en)
Inventor
Leonard G Presta
Joshua Pollack
Linda Liang
Michel Streuli
Venkataraman Sriram
Sayantan Mitra
Nadine Jahchan
Xi Yang
Vladislava Juric
Linnea Haeggblom
Kara Mojica
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of MX2023005841A publication Critical patent/MX2023005841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proporcionan anticuerpos anti-MARCO; también se proporcionan métodos para generar y usar los anticuerpos anti-MARCO.
MX2023005841A 2020-11-18 2021-11-18 Anticuerpos anti-marco y usos de estos. MX2023005841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US202163244662P 2021-09-15 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005841A true MX2023005841A (es) 2023-08-16

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005841A MX2023005841A (es) 2020-11-18 2021-11-18 Anticuerpos anti-marco y usos de estos.

Country Status (10)

Country Link
US (2) US11572407B2 (es)
EP (1) EP4247419A1 (es)
JP (1) JP2023549555A (es)
KR (1) KR20230121759A (es)
AU (1) AU2021382658A1 (es)
CA (1) CA3198579A1 (es)
IL (1) IL302874A (es)
MX (1) MX2023005841A (es)
TW (1) TW202237648A (es)
WO (1) WO2022109178A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059256A1 (en) * 2022-09-15 2024-03-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
JP2010534335A (ja) * 2007-07-24 2010-11-04 アイエスエス イミューン システム スティミュレーション アーベー 全身性エリテマトーデス感受性を予測するための方法及び手段
WO2009114547A2 (en) * 2008-03-10 2009-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
EP3302558A4 (en) 2015-06-01 2019-01-16 The Rockefeller University ANTICANCER AGENTS AND METHODS OF USE
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
EP3574018A4 (en) 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TWI828625B (zh) 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
WO2019036724A2 (en) 2017-08-18 2019-02-21 Celdara Medical Llc CELLULAR THERAPIES TARGETING MOLECULAR MEDIATORS ASSOCIATED WITH DISEASE, FIBROUS, INFLAMMATORY, AND AUTOIMMUNE CONDITIONS
ES2941966T3 (es) 2017-09-28 2023-05-29 Immpact Bio Ltd Una plataforma universal para preparar un receptor de antígeno quimérico inhibidor (ICAR)
AU2018392692A1 (en) 2017-12-22 2020-07-23 Atossa Therapeutics, Inc. Intraductal methods of treatment of breast disorders
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
WO2020065406A2 (en) 2018-09-28 2020-04-02 Immpact-Bio Ltd. Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies
US20220227876A1 (en) * 2018-12-05 2022-07-21 The Council Of The Queensland Institute Of Medical Research Rank antagonists and uses thereof
WO2020142659A2 (en) 2019-01-04 2020-07-09 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
JP2022519378A (ja) 2019-02-08 2022-03-23 グッド ティー セルズ、 インコーポレイテッド がん治療のためのｔ細胞の活性化方法
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
KR20220012261A (ko) 2019-05-07 2022-02-03 이뮤니컴 인코포레이티드 체외 성분채집술에 의한 체크포인트 억제제에 대한 반응 증가
EP3983007A4 (en) 2019-06-11 2023-11-15 Myeloid Therapeutics, Inc. MACROPHAGE-SPECIFIC RECRUITER COMPOSITIONS AND METHODS OF USE
KR20220054305A (ko) 2019-07-31 2022-05-02 온코어 파마, 인크. 면역 회피성 종양의 치료

Also Published As

Publication number Publication date
JP2023549555A (ja) 2023-11-27
CA3198579A1 (en) 2022-05-27
US11572407B2 (en) 2023-02-07
US20220153832A1 (en) 2022-05-19
TW202237648A (zh) 2022-10-01
WO2022109178A9 (en) 2023-07-13
IL302874A (en) 2023-07-01
AU2021382658A1 (en) 2023-07-06
WO2022109178A1 (en) 2022-05-27
US20240084000A1 (en) 2024-03-14
EP4247419A1 (en) 2023-09-27
KR20230121759A (ko) 2023-08-21

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021009138A (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
PH12020551716A1 (en) Anti-ror antibody constructs
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2021016050A (es) Formulaciones transdermicas.
CR20200564A (es) Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021000790A (es) Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
MX2023011927A (es) Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
MX2023005841A (es) Anticuerpos anti-marco y usos de estos.
MX2023004280A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
MX2020008849A (es) Replicas de vino moscatel producidas a partir de los componentes individuales.
PH12021551195A1 (en) Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
MX2021008005A (es) Bibliotecas de peptidos y metodos de uso de las mismas.
MX2023011919A (es) Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos.
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use